Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial.

ABSTRACT:

Purpose

To compare patient-centered outcomes in patients with proliferative diabetic retinopathy (PDR) treated with ranibizumab vs panretinal photocoagulation (PRP).

Design

Randomized clinical trial.

Methods

Setting: Multicenter (55 U.S. sites).

Patient population

Total of 216 adults with 1 study eye out of 305 adults (excluding participants with 2 study eyes, because each eye received a different treatment) with PDR, visual acuity 20/320 or better, no history of PRP.

Intervention

Ranibizumab (0.5 mg/0.05 mL) vs PRP.

Main outcome measures

Change from baseline to 2 years in composite and prespecified subscale scores from the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25), University of Alabama Low Luminance Questionnaire (UAB-

SUBMITTER: Beaulieu WT 

PROVIDER: S-EPMC5215763 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature